Hormone Therapy for Cancer Is a Risk Factor for Relapse of Inflammatory Bowel Diseases
Open Access
- 11 July 2019
- journal article
- research article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 18 (4) , 872-880.e1
Abstract
No abstract availableKeywords
Funding Information
- Merck
- Janssen Pharmaceutica
- Gilead Sciences
- Theravance Biopharma US
- Johnson & Johnson Innovative Medicine
- Ferring Pharmaceuticals
- AbbVie
- Pfizer
- Takeda Pharmaceuticals U.S.A.
- Chemotherapy Foundation
- Eli Lilly and Company
- Shire
This publication has 35 references indexed in Scilit:
- Gender Bias in Autoimmunity Is Influenced by MicrobiotaImmunity, 2013
- Hormone Therapy Increases Risk of Ulcerative Colitis but not Crohn's DiseaseGastroenterology, 2012
- Effects of Cancer Treatment on Inflammatory Bowel Disease Remission and ReactivationClinical Gastroenterology and Hepatology, 2012
- Oral contraceptives, reproductive factors and risk of inflammatory bowel diseaseGut, 2012
- Role of genetic and environmental factors in British twins with inflammatory bowel diseaseInflammatory Bowel Diseases, 2012
- Intestinal Inflammation and CancerGastroenterology, 2011
- Environmental factors in inflammatory bowel disease: A co-twin control study of a Swedish-Danish twin populationInflammatory Bowel Diseases, 2006
- The gastrointestinal tract as target of steroid hormone action: Quantification of steroid receptor mRNA expression (AR, ERα, ERβ and PR) in 10 bovine gastrointestinal tract compartments by kinetic RT-PCRThe Journal of Steroid Biochemistry and Molecular Biology, 2003
- Tissue‐specific expression pattern of estrogen receptors (ER): Quantification of ERα and ERβ mRNA with real‐time RT‐PCRNoteAPMIS, 2001
- Estrogen Receptor α and β Expression in Upper Gastrointestinal Tract with Regulation of Trefoil Factor Family 2 mRNA Levels in Ovariectomized RatsBiochemical and Biophysical Research Communications, 1997